“…GMT was considerably high even for the type 1 Mahoney strain in the three groups after the booster immunization of DTaP-sIPV. The incidence of adverse events (erythema and pyrexia) was higher in Group H than that in Groups M and L, but was not statistically significant [58]. Accordingly, Kaketsuken selected formulation M (1.5, 50, and 50 sDU/0.5 mL/dose, for type 1, 2, and 3, respectively) as optimum doses for the Phase III study.…”